Halozyme Therapeutics, Inc. (HALO) — closed signal from February 13, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 14, 2026.
Predicted vs. what happened
What happened
Reached 21% of the predicted growth at its peak, without hitting the target.
The thesis — published February 13, 2026
There's an important results announcement next week and early hints look strong. If the company surprises positively and raises guidance, the stock could keep rising because it earns steady royalties and partners on drug delivery. Short-term moves can be sharp after earnings, so start small and add only if the report shows clear strength.
Primary drivers
- Earnings can quickly change what investors expect
- Royalty and partner deals make revenue more stable
- Good previews raise the chance of a positive result
- Strong follow-through after earnings can sustain gains
How it played out
HALO: target was not reached by May 14
Lyra published HALO on February 13 at 79.17 for a short-term window ending May 14. The thesis expected 14% growth and a move toward 90.25. It pointed to an important results announcement, possible guidance strength, steady royalties, partner drug-delivery deals, and follow-through after earnings.
Inside the window, HALO peaked at 81.51 on February 17, a 3% gain. It never reached 90.25. By May 14, it ended at 69.21. The thesis did not play out according to the measured price action.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.